Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Re-Challenge in Metastatic Castration-Resistant Prostate Cancer
NCT02656615Phase 2Terminated
- Start
- Jan 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: Response Rate at 12 weeks. Started Jan 2016; status: terminated.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02656615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656615.